International Journal of Cancer最新文献

{"title":"Longitudinal changes in health-related quality of life after a breast cancer diagnosis in sub-Saharan Africa: Evidence from the prospective ABC-DO cohort.","authors":"Shamsudeen Mohammed, Moses Galukande, Allen Naamala, Groesbeck Parham, Leeya Pinder, Angelica Anele, Shadrach Awa Offiah, Annelle Zietsman, Joachim Schüz, Valerie McCormack, Isabel Dos-Santos-Silva","doi":"10.1002/ijc.70350","DOIUrl":"10.1002/ijc.70350","url":null,"abstract":"<p><p>Breast cancer and its treatments impact on women's health-related quality of life, but few studies have assessed these outcomes among survivors in sub-Saharan Africa (SSA). We investigated longitudinal changes in Global Health Status (GHS) and their correlates within the African Breast Cancer-Disparities in Outcomes cohort. Newly diagnosed women (≥18 years) across five SSA countries were recruited in 2014-2017. In four countries, follow-up interviews were conducted 3-monthly over 7 years using the European Organisation for Research and Treatment of Cancer Quality of Life 30-item core questionnaire version 3. Multilevel mixed-effects models identified correlates of GHS. Overall, 1358 women from Namibia, Nigeria, Uganda and Zambia were included, with a mean age of 50.6 (SD = 13.7) years. Median follow-up time was 3 (IQR = 2-5) years, with a median of 18 GHS assessments per woman (IQR = 10-23). GHS was lowest in the first 6 months post-diagnosis but improved gradually thereafter. GHS increased with increasing education (p-value for linear trend [p_t] < .0001), breast cancer awareness (adjusted-odds ratio: 1.32; 95% confidence interval 1.22-1.42), surgical treatment (1.90; 1.53-2.37), family support (1.46; 1.24-1.71) and maintaining pre-diagnosis employment (1.54; 1.41-1.68). In contrast, GHS decreased with increasing age at diagnosis (p_t <.0001), rural residence (0.76; 0.70-0.82), advanced tumour stage at diagnosis (p_t <.0001) and having non-HIV comorbidities (0.74; 0.60-0.92). GHS was not affected by HIV status, but it was higher during COVID-19 lockdowns than pre-/post-lockdown (1.27; 1.09-1.49). These patterns were similar at young and older ages, and in the short- and long-term. The potentially modifiable factors associated with GHS are known to influence breast cancer survival in SSA. Addressing them could improve survivorship and survival from this cancer in the region.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"78-91"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Association of aspirin and ibuprofen use with endometrial cancer risk in the PLCO dataset\".","authors":"Shih-Wei Lai, Kuan-Fu Liao","doi":"10.1002/ijc.70392","DOIUrl":"10.1002/ijc.70392","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"280"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances.","authors":"Dezhong Jin, Liangwang Zhong, Lai Chen","doi":"10.1002/ijc.70419","DOIUrl":"10.1002/ijc.70419","url":null,"abstract":"<p><p>Lung cancer, the leading cause of global cancer-related mortality, is categorized into small-cell and non-small-cell subtypes. The heterogeneous non-small-cell lung cancer group is further subcategorized primarily into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each underpinned by distinct molecular alterations. Although traditional serum biomarkers aid in subtype differentiation and treatment monitoring, their utility is limited by challenges such as poor specificity due to inflammatory confounders and the difficulty of dynamically tracking therapeutic resistance. Recent advances have identified emergent subtype-specific biomarkers that reflect metabolic reprogramming, epigenetic dysregulation, stemness signatures, and interactions within the immune microenvironment. By integrating analytes such as ctDNA, exosomal RNAs, and urinary DNA with multi-analyte panels and advanced imaging, liquid biopsies offer a promising avenue to enhance early detection accuracy, prognostication, and dynamic therapy monitoring. Nevertheless, the clinical adoption is hindered by several challenges, including incomplete validation, the need for technical standardization, intratumoral heterogeneity, and inter-ethnic variability. The convergence of artificial intelligence (AI)-enhanced multi-omics with biomarker-guided therapeutics represents a transformative strategy with the potential to overcome resistance, mitigate ethnic disparities, and ultimately transform lung cancer into a chronic, manageable disease. Therefore, prioritizing clinically validated AI-integrated platforms is pivotal to achieve precision oncology.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"30-53"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147454968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological reflections on real-world electronic health records analyses in oncology.","authors":"Andreas Bjerrum","doi":"10.1002/ijc.70457","DOIUrl":"10.1002/ijc.70457","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"9-10"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Comments on \"Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China\".","authors":"Jiali Quan, Qi Chen, Ting Wu","doi":"10.1002/ijc.70437","DOIUrl":"10.1002/ijc.70437","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"283-284"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147571360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-specific breast cancer incidence by subtype, TNM stage and screening status in Sweden 2008-2019 estimated with multiple imputation.","authors":"Leo Gkekos, Katrín Ásta Gunnarsdóttir, Keith Humphreys, Irma Fredriksson, Anna L V Johansson","doi":"10.1002/ijc.70355","DOIUrl":"10.1002/ijc.70355","url":null,"abstract":"<p><p>Breast cancer incidence in women increases with age, but less is known about which subtypes contribute the most at different ages. We describe age-specific breast cancer incidence rates in Sweden by subtype, TNM stage and screening status. Population-based data were retrieved from the Swedish National Quality Register for Breast Cancer on 89,322 invasive breast cancer cases diagnosed 2008-2019 in women ≥18 years. Breast cancer subtypes were defined by estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), and grade. Poisson regression with multiple imputation estimated proportions and incidence rates. In women <40 years, the breast cancer incidence rates were low with luminal HER2, HER2 positive and triple-negative breast cancer (TNBC) accounting for 57% of tumors. During screening ages (40-74 years), luminal A-like tumors accounted for 59% and their incidence rate increased by age. Luminal A-like tumors were more often screen-detected (70%) compared to HER2 positive (45%) and TNBC (42%). At age 75 years, the incidence rates declined temporarily for all subtypes, and remained mostly stable in older ages, although the luminal A-like rates did not reach the same levels as 40-74 years. In the screening ages, stage I incidence rates were increased, especially for the luminal A-like subtype, while in post-screening ages (≥75 years), stage II incidence rates were highest, especially for luminal B-like, luminal HER2 and TNBC subtypes. Age-specific incidence patterns vary by subtype and are all influenced by screening. Future diagnostic and preventive interventions should consider these age-specific patterns.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"101-110"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146163256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.","authors":"Min-Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues-van Tol, Theresa Link, Anton Scharl, Elisabeth C Sturm-Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer-Schalke, Jochen Schmitt, Michael Schlander","doi":"10.1002/ijc.70388","DOIUrl":"10.1002/ijc.70388","url":null,"abstract":"<p><p>In Germany, the German Cancer Society (Deutsche Krebsgesellschaft [DKG]) accredits hospitals to ensure high-quality cancer treatment through adherence to clinical guidelines and a multidisciplinary approach. Evidence suggests certified hospitals (CHs) achieve better clinical outcomes and prognoses than non-certified hospitals (NCHs). However, additional services required for certification incur substantial, unreimbursed costs, necessitating a focused cost-effectiveness evaluation. This retrospective cohort study utilized anonymized administrative routine healthcare data from Allgemeine Ortskrankenkasse, Germany's largest statutory health insurance. The study sample comprised 143,720 incident breast cancer (BC) patients treated between 2009 and 2017 across both CHs and NCHs. A health system perspective was used in this cost-effectiveness analysis. Direct medical costs (inpatient, outpatient, medication, and certification) were compared between CHs and NCHs. Life-years gained (LYG) were calculated from 5-year restricted mean survival time. The incremental cost-effectiveness ratio (ICER), quantified as cost per LYG, served as the primary outcome measure, reported in 2024 euro. Treatment in CHs significantly improved breast cancer survival, yielding 201 LYG per 1000 patients (95% confidence interval: 185-216). Accounting for €1.5 M in certification-related costs and marginal direct medical costs, the total incremental cost was €1.81 M per 1000 patients. This resulted in an ICER of €9036 per LYG. Despite the financial investment required for DKG certification, BC treatment in CHs provided significant survival benefits at a reasonable incremental cost, reinforcing the clinical and economic value. These findings offer critical insights for hospital authorities and healthcare policymakers, supporting the continued investment in certification.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"159-172"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.","authors":"Patrick Marschner, Kai Ringwald, Marc Thill, Mark-Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser-Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker","doi":"10.1002/ijc.70433","DOIUrl":"10.1002/ijc.70433","url":null,"abstract":"<p><p>Cancer patients prone to toxicities might benefit from dose reduction over fixed-dose recommendations. We develop a predictive index to identify patients with increased probability of dose reduction, intolerable toxicities, or therapy discontinuation (hereafter: dose reduction) in metastatic breast cancer (MBC) and compare real-world effectiveness of reduced (RSD) versus full starting dose (FSD) using this index. This analysis included 618 patients with HR-positive, HER2-negative MBC from the prospective, observational, multicenter registry OPAL (NCT03417115), receiving first-line palbociclib (n = 386) or ribociclib (n = 232) plus endocrine therapy. A logistic regression model was employed to derive the predictive index. Inverse probability of treatment weighting was used to emulate a head-to-head comparison of RSD and FSD by analyzing progression-free (PFS) and overall survival (OS). Within 6 months, 215 patients (35%) underwent dose reduction, including 109 (51%) with RSD. Predictors for dose reduction were age ≥65 years and Charlson comorbidity index (CCI) ≥1. Among patients with increased probability of dose reduction (index ≥1: ≥65 years and/or CCI ≥ 1), median PFS and OS were 30.1 [21.7, 54.0] and 57.6 [40.0, NA] months with RSD vs. 29.3 [24.9, 32.0] and 43.1 [38.8, 50.3] months with FSD. For low-probability patients (index = 0: <65 years and CCI = 0), median PFS and OS were 17.6 [9.1, 29.8] and 32.9 [23.1, 40.9] months with RSD vs. 24.5 [19.8, 32.0] and 54.2 [48.8, NA] months with FSD. In this real-world MBC setting, patients ≥65 years and/or with CCI ≥ 1 had an increased probability of dose reduction and may benefit from RSD, as this yielded outcomes comparable to FSD. Younger, fitter patients may require full dosing. Future studies, ideally randomized controlled trials, should aim to confirm these findings.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"244-256"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on \"Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China\".","authors":"Man Sun, Jing-Mian Jiao, Jun Chen","doi":"10.1002/ijc.70439","DOIUrl":"10.1002/ijc.70439","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"281-282"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147571337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions for oral cancer prevention: An evidence and gap map.","authors":"Suzanne Tanya Nethan, Maria Eduarda Pérez-de-Oliveira, Fiona Campbell, Alan Roger Santos-Silva, Béatrice Lauby-Secretan","doi":"10.1002/ijc.70391","DOIUrl":"10.1002/ijc.70391","url":null,"abstract":"<p><p>Oral cancer is the 16th most common cancer globally, but oral cancer prevention is limited. We developed five evidence and gap maps using 188 studies identified in the International Agency for Research on Cancer Handbooks of Cancer Prevention Volume 19 on Oral Cancer Prevention, across five categories of interventions: (1) exposure to preventive dietary agents, (2) quitting exposure to oral cancer risk factors, (3) interventions for smokeless tobacco (SLT) and areca nut cessation, (4) SLT and areca nut control policies, and (5) secondary prevention. The largest number of studies addressed the effect of quitting exposure to a risk factor (n = 57) and control policy interventions (n = 51); 34 studies focused on interventions for SLT and areca nut cessation, 32 evaluated preventive dietary agents, and only 15 assessed secondary prevention. Numerous research gaps were identified, including few youth-targeted studies, a paucity of informative studies evaluating risk reversal upon cessation of use of SLT or areca nut with or without tobacco, negligible evidence on interventions for cessation of use of areca nut with or without tobacco, minimal literature on areca nut control policies, and few studies on screening of high-risk individuals. Overall, the findings highlight the need for further research on multiple areas of SLT and areca nut control in high-burden regions. The findings can inform public health decision-making and support more targeted, evidence-based public health strategies to reduce the burden of oral cancer globally.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"188-197"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147275338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}